Synthesis of new benzoxazinone derivatives as neuropeptide Y5 antagonists for the treatment of obesity

Journal of Medicinal Chemistry

Volumn 48, Issue 6, 2005, Pages 2080-2092

  Torrens, Antoni ^a   Mas, Josep ^a   Port, Adriana ^a   Castrillo, José Aurelio ^a   Sanfeliu, Olga ^a   Guitart, Xavier ^a   Dordal, Alberto ^a   Romero, Gonzalo ^a   Fisas, Ma Angeles ^a   Sánchez, Elisabeth ^a   Hernández, Enrique ^a   Pérez, Pilar ^a   Pérez, Raquel ^a   Buschmann, Helmut ^b  

^a Laboratorios Dr Esteve SA   (Spain)

^b Department of Research ^*

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (8 METHYL 2 OXO 4H BENZO [1,3]OXAZIN 1 YL)PIPERIDIN 1 YL N (9 OXO 9H FLUOREN 3 YL)ACETAMIDE; BENZOXAZINONE DERIVATIVE; CYCLIC AMP; N (4 CHLOROPHENYL) 2 [4 (2 OXO 4H BENZO OXAZIN 1 YL)PIPERIDIN 1 YL]ACETAMIDE HYDROCHLORIDE; NEUROPEPTIDE Y5 RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; FOOD INTAKE; IN VITRO STUDY; MALE; NONHUMAN; OBESITY; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-OBESITY AGENTS; BENZOXAZINES; CELL LINE; CYCLIC AMP; EATING; FLUORENES; FORSKOLIN; MALE; OXAZINES; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, NEUROPEPTIDE Y; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 20144370409     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049599u     Document Type: Article

References (59)

1. Friedman, J. M. Obesity in the new millennium. Nature 2000, 404, 632-634.
2. Kopelman, P. G. Obesity as a medical problem. Nature 2000, 404, 635-643.
3. Tatemoto, K.; Cariquist, M.; Mutt, V. Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982, 296, 659-660.
4. Allen, Y. S.; Adrian, T. E.; Allen, J. M.; Tatemoto, K.; Crow, J.; Bloom, S. R.; Polak, J. M. Neuropeptide Y distribution in the rat brain. Science 1983, 221, 877-879.
5. O'Donohue, T. L.; Chronwall, B. M.; Pruss, R. M.; Mezey, E.; Kiss, J. Z.; Eiden, L. E.; Massari, V. J.; Tessel, R. E.; Pickel, V. M.; Dimaggio, D. A.; Hotchkiss, W. R.; Crowley, W. R.; Zukowska-Grojec, Z. Neuropeptide Y and peptide YY neuronal and endocrine systems. Peptides 1985, 6, 755-768.
6. Wahlestedt, C.; Reis, D. J. Neuropeptide Y-related peptides and their receptors-are the receptors potential therapeutic drug targets? Annu. Rev. Pharmacol. Toxicol. 1993, 32, 309-352.
7. Grundemar, L.; Hakanson, R. Multiple neuropeptide Yreceptors are involved in cardiovascular regulation. Peripheral and central mechanisms. Gen. Pharmacol. 1993, 24, 785-796.
8. Lundberg, J. M.; Franco-Cerecada, A.; Lacroix, J. S.; Pernow, J. Neuropeptide Y and sympathetic neurotransmission. Ann. N. Y. Acad. Sci. 1990, 611, 166-174.
9. McDermott, B. J.; Millat, B. C.; Piper, H. M. Cardiovascular effects of neuropeptide Y: receptor interactions and cellular mechanisms. Cardiovasc. Res. 1993, 27, 893-905.
10. Grundemar, L.; Hakanson, R. Neuropeptide Y effector systems: perspectives for drug development. Trends. Pharmacol. Sci. 1994, 15, 153-159.
11. Heilig, M.; McLeod, S.; Brot, M.; Heinrichs, S. C.; Menzaghi, F.; Koob, G. F.; Britton, K. T. Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology 1993, 8, 357-363.
12. Klapstein, G. J.; Colmers, W. F. Neuropeptide Y suppresses epileptiform activity in rat hippocampus in vitro. J. Neurophysiol. 1997, 78, 1651-1661.
13. McAuley, M.; Westfall, T. C. Possible location and function of neuropeptide Y receptor subtypes in the rat mesenteric arterial bed. J. Pharmacol. Exp. Ther. 1992, 261, 863-868.
14. Munglani, R.; Hudspith, M. J.; Hunt, S. P. The therapeutic potential of neuropeptide Y. Analgesic, anxiolytic and antihypertensive. Drugs 1996, 52, 371-389.
15. Wahlestedt, C.; Yanaihara, N.; Hakanson, R. Evidence for different pre- and post-junctional receptors for neuropeptide Y and related peptides. Regul. Pept., 1986, 13, 307-318.
16. Wahlestedt, C.; Pich, E. M.; Koob, G. F.; Yee, F.; Heilig, M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 1993, 259, 528-531.
17. Wieland, H. A.; Hamilton, B. S.; Krist, B.; Doods, H. N. The role of NPY in metabolic homeostasis: implications for obesity therapy. Expert Opin. Invest. Drugs 2000, 9, 1327-1346.
18. Zimanyi, I, A.; Pointdexter, G. S. NPY-ergic agents for the treatment of obesity. Drug Dev. Res. 2000, 51, 94-111.
19. Brief, D. J.; Sipols, A. J.; Woods, S. C. Intraventricular neuropeptide Y injections stimulate food intake in lean, but not obese Zucker rats. Physiol. Behav. 1992, 51, 1105-1110.
20. Kalra, S. P.; Dube, M. G.; Pu, S.; Xu, B.; Horvath, T. L.; Kalra, P. S. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr. Rev. 1999, 20, 68-100.
21. Sainsbury, A.; Rohner-Jeanrenaud, F.; Grouzmann, E.; Jeanrenaud, B. Acute intracerebroventricular administration of neuropeptide Y stimulates corticosterone output and feeding but not insulin output in normal rats. Neuroendocrinology 1996, 63, 318-326.
22. Stanley, B. G. Neuropeptide Y in multiple hypothalamic sites controls eating behavior, endocrine and autonomic systems of body energy balance. In The Biology of Neuropeptide Y and Related Peptides; Colmers, W. F., Wahlestedt, C., Eds.; Humana Press: Totowa, NJ, pp 457-510.
23. Turnbull, A. V.; Ellershaw, L.; Masters, D. J.; Birtles, S.; Boyer, S.; Carroll, D.; Clarkson, P.; Loxham, S. J.; McAulay, P.; Teague, J. L.; Foote K. M.; Pease, J. E.; Block, M. H. Selective antagonism of the NPY Y5 receptor does not have a major effect on feeding in rats. Diabetes 2002, 51, 2441-2449.
24. Della-Zuana, O.; Revereault, L.; Beck-Sickinger, A.; Monge, A.; Caignard, D.-H.; Fauchère, J.-L.; Henlin, J.-M.; Audinot, V.; Boutin, J. A.; Chamorro, S.; Félétou, M.; Levens, N. A potent and selective NPY Y5 antagonist reduces food intake but not through blockade of the NPY Y5 receptor. Int. J. Obes. 2004, 28, 628-639.
25. Erickson, J. C.; Clegg, K. E.; Palmiter, R. D. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 1996, 381, 415-421.
26. Erickson, J. C.; Hollopeter, G.; Palmiter, R. D. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science 1996, 274, 1704-1707.
27. Bischoff, A.; Michel, M. C. Emerging functions for neuropeptide Y5 receptors. Trends Pharmacol. Sci. 1999, 20, 104-106.
28. Blomqvist, A. G.; Herzog, H. Y-receptor subtypes - how many more? Trends Neurosci. 1997, 20, 294-298.
29. Dumont, Y.; Martel, J. C.; Fournier, A.; St-Pierre, S.; Quirion, R. Neuropeptide Y and neuropeptide Y receptor subtypes in brain and peripheral tissue. Prog. Neurobiol. 1992, 38, 125-167.
30. Gehlert, D. R. Subtypes of receptors for neuropeptide Y: implications for targeting of therapeutics. Life Sci. 1994, 55, 551-562.
31. Inui, A. Neuropeptide Y feeding receptors: are multiple subtypes involved? Trends Pharmacol. Sci. 1999, 20, 43-46.
32. Bard, J. A.; Walker, M. W.; Branchek, T. A.; Weinshank, R. L. Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY. J. Biol. Chem. 1995, 270, 26762-26765.
33. Gerald, C.; Walker, M. W.; Vaysse, P. J.; He, C.; Branchek, T. A.; Weinshank, R. L. Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY. J. Biol. Chem. 1995, 270, 26758-26761.
34. Herzog, H.; Hort, Y. J.; Ball, H. J.; Hayes, G.; Shine, J.; Selbie, L. A Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 5794-5798.
35. Larhammar, D.; Blomqvist, A. G.; Yee, F.; Jazin, E.; Yoo, H.; Wahlested, C. Cloning and functional expression of a human neuropeptide Y/peptide YY receptor of the Y1. J. Biol. Chem. 1992, 267, 10935-10938.
36. Lundell, I.; Blomqvist, A. G.; Berglund, M. M.; Schober, D. A.; Johnson, D.; Statnick, M. A.; Gadski, R. A.; Gehlert, D. R.; Larhammar, D. Cloning of a human receptor of the NPY receptor family with high affinity for pancreatic polypeptide and peptide YY. J. Biol. Chem. 1995, 270, 29123-29128.
37. Weinberg, D. H.; Sirinathsinghji, D. J.; Tan, C. P.; Shiao, L. L.; Morin, N.; Rigby, M. R.; Heavens, R. H.; Rapoport, R. H.; Bayne, M. L.; Cascieri, M. A.; Strader, C. D.; Linemeyer, D. L.; MacNeil, D. J. Cloning and expression of a novel neuropeptide Y receptor. J. Biol. Chem. 1996, 271, 16435-16438.
38. Block, M. H.; Boyer, S.; Barilsford, W.; Brittain, D. R.; Carroll, D.; Chapman, S.; Clarke, D. S.; Donald, C. S.; Foote, K. M.; Godfrey, L.; Ladner, A.; Marsham, P. R.; Masters, D. J.; Mee, C. D.; O'Donovan, M. R.; Pease, J. E.; Pickup, A. G.; Rayner, J. W.; Roberts, A.; Schofield, P.; Suleman, A.; Turnbull, A. Discovery and optimization of a series of carbazole ureas as NPY5 antagonists for the treatment of obesity. J. Med. Chem. 2002, 45, 3509-3523.
39. Cabrele, C.; Langer, M.; Bader, R., Wieland, H. A.; Doods, H. N.; Zerbe, O.; Beck-Sickinger, A. G. The first selective agonist for the neuropeptide YY5 receptor increases food intake in rats. J. Biol. Chem. 2000, 275, 36043-36048.
40. Gerald, C.; Walker, M. W.; Criscione, L.; Gustafson, E. L.; Batzl-Hartmann, C.; Smith, K. E.; Vaysse, P.; Durkin, M. M.; Laz, T. M.; Linemeyer, D. L.; Schaffhauser, A. O.; Whitebread, S.; Hofbauer, K. G.; Taber, R. I.; Branchek, T. A.; Weinshank, R. L. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 1996, 382, 168-171.
41. Haynes, A. C.; Arch, J. R.; Wilson, S.; McClue, S.; Buckingham, R. E. Characterisation of the neuropeptide Y receptor that mediates feeding in the rat: a role for the Y5 receptor?. Regul. Pept. 1998, 75, 355-361.
42. Kask, A.; Vasar, E.; Heidmets, L.-T.; Allikmets, L.; Wikberg, J. E. S. Neuropeptide Y Y(5) receptor antagonist CGP71683A: the effects on food intake and anxiety-related behavior in the rat. Eur. J. Pharmacol. 2001, 414, 215-224.
43. McCrea, K.; Wisialowski, T.; Cabrele, C.; Church, B.; Beck-Sickinger, A., Kraegen, E.; Herzog, H. 2-36[K4,RYYSA(19-23)]-PP a novel Y5-receptor preferring ligand with strong stimulatory effect on food intake. Regul. Pept. 2000, 87, 47-58.
44. Parker, E. M.; Balasubramaniam, A.; Guzzi, M.; Mullins, D. E.; Salisbury, B. G.; Sheriff, S.; Witten, M. B.; Hwa, J. J. [D-Trp-(34)] neuropeptide Y is a potent and selective neuropeptide Y Y(5) receptor agonist with dramatic effects on food intake. Peptides 2000, 21, 393-399.
45. Polidori, C.; Ciccocioppo, R.; Regoli, D.; Massi, M. Neuropeptide Y receptor(s) mediating feeding in the rat: characterization with antagonists. Peptides 2000, 21, 29-35.
46. (a) Rueger, H.; Schmidlin, T.; Rigollier, P.; Yamaguchi, Y.; Tintelnot-Blomley, M.; Schilling, W.; Criscione, L.; Mah, R. Preparation of 2-Aminoquinazolines as Neuropeptide Y Subtype Y5 Receptor Antagonists. PCT Int. Appl. WO 9720803, 1997 (Novartis Ag.).
47. (b) Fotsch, C.; Sonnenberg, NC.; Hale, C.; Karbon, W.; Norman, M. H. Synthesis and Structure-Activity Relationships of Trisubstituted Phenyl Urea Derivatives as Neuropeptide Y5 Receptor Antagonists. J. Med. Chem. 2001, 44, 2344-2356 (Amgen Inc.).
48. (c) Islam, I.; Dhanoa, D. S.; Finn, J. M.; Du, P.; Gluchowski, C.; Jeon, Y. T. Preparation of aryl sulfonamide and sulfamide derivatives which bind selectively to the human Y5 receptor. PCT Int. Appl. WO 97/19682, 1997 (Synaptic Pharm.).
49. (d) Fukami, T.; Fukuroda, T.; Kanatani, A.; Ihara, M. Preparation of Urea Moiety-Containing Pyrazole Derivatives as Neuropeptide Y Antagonists. PCT Int. Appl. WO 9824768, 1998 (Banyu Pharmaceutical Co. Ltd.).
50. (e) Block, M. H.; Donald, S. C.; Foote, K.; Schofield, P.; Marsham, P. R. Carbazole Derivatives and Their Use as Neuropeptide Y5 Receptor Ligands. PCT Int. Appl. WO 01/07409, 2001 (Astrazeneca U.K. Ltd).
51. (f) Connell, R. D.; Lease, T. G.; Ladouceur, G. H.; Osterhout, M. H. Preparation of Amide Derivatives as Selective Neuropeptide Y Receptor Antagonists. PCT Int. Appl. WO 9835957, 1998 (Bayer Corp.).
52. (a) Torrens, A.; Castrillo, J. A.; Frigola, J.; Mas, J.; Dordal, A.; Fisas, M. A. Preparation of benzoxazinones as neuropeptide Y 5 (NPY5) regulators. PCT Int. Appl. WO 2003084952, 2003.
53. (b) Torrens, A.; Castrillo, J. A.; Frigola, J. Preparation of benzoxazinones as neuropeptide Y5 (NPY5) receptor ligands for treatment of central nervous system diseases. PCT Int. Appl. WO 2003084939, 2003.
54. Hu, Y.; Bloomquist, B. T.; Cornfield, L. J.; DeCarr, L. B.; Flores-Riveros, J. R.; Friedman, L.; Jiang, P.; Lewis-Higgins, L.; Sadlowski, Y.; Schaefer, J.; Velazquez, N.; McCaleb, M. L. Identification of a novel hypothalamic neuropeptide Y receptor associated with feeding behavior. J. Biol. Chem. 1998, 271, 26315-26319.
55. Bell, I. M.; Erb, J. M.; Freidinger, R. M.; Gallichio, S. N.; Guare, J. P.; Guidotti, M. T.; Halpin, R. A.; Hobbs, D. W.; Homnick, C. F.; Kuo, M. S.; Lis, E. V.; Mathre, D. J.; Michelson, S. R.; Pauluczyk, J. M.; Pettibone, D. J.; Reiss, D. R.; Vickers, S.; Williams, P. D.; Woyden C. J. Development of Orally Active Oxytocin Antagonists: Studies on 1-(1-{4-[1-(2-Methyl-1-oxidopyridin-3- ylmethyl)piperidin-4-yloxy]-2-methoxybenzoyl}piperidin-4-yl)-1,4-dihydrobenz[d] [1,3]oxazin-2-one (L-372,662) and Related Pyridines. J. Med. Chem. 1998, 41, 2146-2163.
56. Gnilka, J.; Luczak, J.; Budzisz, T. (Osrodek Badawczo-Rozwojowy Barwnikow, Pol) Patent Application PL 72-155635, 1975.
57. Fotsch, C.; Sonnenberg, J. D.; Chen, N.; Hale, C.; Karbon, W.; Norman, M. H. Synthesis and Structure-Activity Relationships of Trisubstituted Phenyl Urea Derivatives as Neuropeptide Y5 Receptor Antagonists. J. Med. Chem. 2001, 44, 2344-2356.
58. Gilman, H.; Avakian, S. Some dialkylamino derivatives of dibenzothiophene. J. Am. Chem. Soc. 1946, 68, 1514-1515.
59. Kotler-Brajtburg, J. Search for antiserotonin substances in the group of quinoline derivatives. II. N,N-Dimethylaminoquinolines and their quaternary salts. Acta Phys. Pol. 1967, 24, 127-131.